Literature DB >> 23712606

Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer.

Jun-Jun Qiu1, Jun-Jie Guo, Tian-Jiao Lv, Hong-Yan Jin, Jing-Xin Ding, Wei-Wei Feng, Ying Zhang, Ke-Qin Hua.   

Abstract

Altered expression of centromere protein-A (CENP-A) is observed in various types of human cancers. However, the clinical significance and pathological role of CENP-A in epithelial ovarian cancer (EOC) remains unclear. The main objective of this investigation was to clarify the relationships between CENP-A expression and the clinicopathological features of patients with EOC. Real-time quantitative PCR and Western blot were performed to examine CENP-A expression in 20 pairs of fresh-frozen EOC tissues and corresponding noncancerous tissues. Using immunohistochemistry, we performed a retrospective study of the CENP-A expression levels on 120 archival EOC paraffin-embedded samples. Prognostic outcomes correlated with CENP-A were examined using Kaplan-Meier analysis and Cox proportional hazards model. Our results showed that the expression levels of CENP-A mRNA and protein in EOC tissues were both significantly higher than those in noncancerous tissues. By immunohistochemistry, the data revealed that high CENP-A expression was significantly correlated with pathological grade (P = 0.02) and International Federation of Gynecology and Obstetrics stage (P = 0.006). Consistent with these results, we found that high expression of CENP-A was significantly correlated with poor survival in EOC patients (P < 0.001). Furthermore, Cox regression analyses showed that CENP-A expression was an independent predictor of overall survival. Our data suggest that CENP-A could play an important role in EOC and might serve as a valuable prognostic marker and potential target for gene therapy in the treatment of EOC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712606     DOI: 10.1007/s13277-013-0860-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  13 in total

1.  Centromere identity maintained by nucleosomes assembled with histone H3 containing the CENP-A targeting domain.

Authors:  Ben E Black; Lars E T Jansen; Paul S Maddox; Daniel R Foltz; Arshad B Desai; Jagesh V Shah; Don W Cleveland
Journal:  Mol Cell       Date:  2007-01-26       Impact factor: 17.970

2.  Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Authors:  Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Journal:  Clin Cancer Res       Date:  2010-11-01       Impact factor: 12.531

Review 3.  Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis.

Authors:  Matteo Rota; Elena Pasquali; Lorenza Scotti; Claudio Pelucchi; Irene Tramacere; Farhad Islami; Eva Negri; Paolo Boffetta; Rino Bellocco; Giovanni Corrao; Carlo La Vecchia; Vincenzo Bagnardi
Journal:  Gynecol Oncol       Date:  2012-03-23       Impact factor: 5.482

4.  MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.

Authors:  Lingeng Lu; Peter Schwartz; Luca Scarampi; Thomas Rutherford; Emilie Marion Canuto; Herbert Yu; Dionyssios Katsaros
Journal:  Gynecol Oncol       Date:  2011-05-14       Impact factor: 5.482

5.  Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer.

Authors:  M Wang; Y He; L Shi; C Shi
Journal:  Eur J Gynaecol Oncol       Date:  2011       Impact factor: 0.196

6.  Expression and prognostic significance of centromere protein A in human lung adenocarcinoma.

Authors:  Qing Wu; Yi-Ming Qian; Xiang-Li Zhao; Shou-Mei Wang; Xiao-Jun Feng; Xin-Fang Chen; Shu-Hui Zhang
Journal:  Lung Cancer       Date:  2012-04-28       Impact factor: 5.705

7.  Breast-feeding and risk of epithelial ovarian cancer.

Authors:  S J Jordan; K L Cushing-Haugen; K G Wicklund; J A Doherty; M A Rossing
Journal:  Cancer Causes Control       Date:  2012-04-24       Impact factor: 2.506

8.  Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

Authors:  Liangdan Tang; Junzheng Yang; Shu-Kay Ng; Noah Rodriguez; Pui-Wah Choi; Allison Vitonis; Kui Wang; Geoffrey J McLachlan; Robert J Caiazzo; Brian C-S Liu; William R Welch; Daniel W Cramer; Ross S Berkowitz; Shu-Wing Ng
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162

9.  Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.

Authors:  Susan L McGovern; Yuan Qi; Lajos Pusztai; William F Symmans; Thomas A Buchholz
Journal:  Breast Cancer Res       Date:  2012-05-04       Impact factor: 6.466

10.  ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth.

Authors:  Yongmei Li; Zhi Zhu; Shuhui Zhang; Danghui Yu; Hongyu Yu; Lina Liu; Xiaozhe Cao; Li Wang; Hengjun Gao; Minghua Zhu
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

View more
  33 in total

Review 1.  No longer a nuisance: long non-coding RNAs join CENP-A in epigenetic centromere regulation.

Authors:  Silvana Rošić; Sylvia Erhardt
Journal:  Cell Mol Life Sci       Date:  2016-01-09       Impact factor: 9.261

Review 2.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

Review 3.  Chromatin dynamics during the cell cycle at centromeres.

Authors:  Sebastian Müller; Geneviève Almouzni
Journal:  Nat Rev Genet       Date:  2017-01-31       Impact factor: 53.242

4.  The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.

Authors:  Rocío Montes de Oca; Zachary A Gurard-Levin; Frédérique Berger; Haniya Rehman; Elise Martel; Armelle Corpet; Leanne de Koning; Isabelle Vassias; Laurence O W Wilson; Didier Meseure; Fabien Reyal; Alexia Savignoni; Bernard Asselain; Xavier Sastre-Garau; Geneviève Almouzni
Journal:  Mol Oncol       Date:  2014-11-20       Impact factor: 6.603

Review 5.  Altered primary chromatin structures and their implications in cancer development.

Authors:  Angelo Ferraro
Journal:  Cell Oncol (Dordr)       Date:  2016-03-23       Impact factor: 6.730

6.  Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells.

Authors:  Qing Wu; Yong-Feng Chen; Jie Fu; Qi-Han You; Shou-Mei Wang; Xue Huang; Xiao-Jun Feng; Shu-Hui Zhang
Journal:  Cell Oncol (Dordr)       Date:  2014-09-17       Impact factor: 6.730

7.  CENP-A overexpression promotes distinct fates in human cells, depending on p53 status.

Authors:  Daniel Jeffery; Alberto Gatto; Katrina Podsypanina; Charlène Renaud-Pageot; Rebeca Ponce Landete; Lorraine Bonneville; Marie Dumont; Daniele Fachinetti; Geneviève Almouzni
Journal:  Commun Biol       Date:  2021-03-26

8.  ARID3B Directly Regulates Ovarian Cancer Promoting Genes.

Authors:  Alexander Bobbs; Katrina Gellerman; William Morgan Hallas; Stancy Joseph; Chao Yang; Jeffrey Kurkewich; Karen D Cowden Dahl
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

9.  Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.

Authors:  Chi-Chen Huang; Ding-Yen Lin; Yi-Chao Lee; Wen-Chang Chang; Kuen-Haur Lee
Journal:  PeerJ       Date:  2015-11-05       Impact factor: 2.984

10.  Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication?

Authors:  Mery Giantin; Anna Granato; Chiara Baratto; Laura Marconato; Marta Vascellari; Emanuela M Morello; Antonella Vercelli; Franco Mutinelli; Mauro Dacasto
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.